Alpha Tau Medical Ltd. (DRTS), a clinical-stage oncology company pioneering alpha-radiation cancer therapy, is accelerating its clinical and regulatory progress in 2025, with several U.S. and international trials underway and new FDA approvals setting the stage for a pivotal year.
Q1, 2025 Financial Performance:
For the first quarter ended March 31, 2025, Alpha Tau reported a net loss of $8.7 million, or $0.12 per share, compared to a net loss of $8.0 million, or $0.11 per share, in the same period in 2024.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.